DMX Pharma

Pharma

DMX Pharma is a leading Italian group offering fully integrated solutions for the formulation and production of pharmaceutical products, with a strong export-oriented focus on a global scale.

Vai al sito web

Fund

Current stake

Quota ingresso

4.9%

Data investimento

November 2025

Co-investitori

The Club Dealers

Status

In portfolio

strategy

Fondo Italiano d’Investimento acquires NPO Torino S.r.l.

Fondo Italiano d’Investimento SGR: New Board of Directors Appointed for the 2025–2028 Term

Fondo Italiano d’Investimento: FIPEC co-Invests in BV Tech, Spindox, and Else Solutions

Fondo Italiano d’Investimento Acquires Stake in Santangelo Group

Fondo Italiano d’Investimento and Human Foundation: the Impact Investing market in Europe is worth €230 billion

LIUC Business School launches Observatory on the Private Capital Secondary Market in collaboration with Fondo Italiano d’Investimento SGR and Terzi & Partners

DMX Pharma

Pharma

Co-investments

Private Equity

Fondo Italiano d’Investimento acquires NPO Torino S.r.l.

Fondo Italiano d’Investimento SGR: New Board of Directors Appointed for the 2025–2028 Term

Fondo Italiano d’Investimento: FIPEC co-Invests in BV Tech, Spindox, and Else Solutions

Fondo Italiano d’Investimento Acquires Stake in Santangelo Group

Fondo Italiano d’Investimento and Human Foundation: the Impact Investing market in Europe is worth €230 billion

LIUC Business School launches Observatory on the Private Capital Secondary Market in collaboration with Fondo Italiano d’Investimento SGR and Terzi & Partners

Fondo Italiano d’Investimento: FICC II surpasses 500 million euros in raised capital

Fondo Italiano d’Investimento: FIPEC completes additional closing of €113 million

Fondo Italiano d’Investimento: first closing at 230 million euros for FOF Private Equity Italia Tre. Fundraising target at 600 million euros

Fondo Italiano d’Investimento acquires a majority stake in Scatolificio del Garda S.p.A.

Related Investments